Haematology

2013

1. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does -7/7q- detection by FISH have prognostic value?

   Leukemia Research, Vol. 37, Núm. 4, pp. 416-421

2. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)

   Medical Mycology, Vol. 51, Núm. 2, pp. 150-154

3. Erythrocytosis in a child due to Hb andrew-minneapolis [β144(HC1) Lys→Asn (AAG>AAT or AAC)] associated with a Spanish (δβ) ;0-thalassemia

   Hemoglobin, Vol. 37, Núm. 1, pp. 48-55

4. Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónica

   Medicina Clinica

5. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

   Blood, Vol. 122, Núm. 8, pp. 1448-1454

6. Javier, el hombre

   F. Javier Fortea Pérez: Universitatis Ovetensis Magister. Estudios en homenaje (Ediciones de la Universidad de Oviedo), pp. 589-594

7. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?)

   European Journal of Haematology, Vol. 91, Núm. 4, pp. 361-368

8. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia

   Human Pathology, Vol. 44, Núm. 8, pp. 1696-1699

9. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis

   Leukemia, Vol. 27, Núm. 11, pp. 2149-2156

10. Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment

    Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952

11. Primary familial congenital erythrocytosis: Two novel EPOR mutations found in Spain

    International Journal of Laboratory Hematology

12. Tratamiento de infecciones fúngicas en pacientes hematológicos de alto riesgo. La respuesta de AmBisome no se modifica con el uso previo de azoles de amplio espectro

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 1, pp. 64-69

13. Tratamiento de las infecciones fúngicas invasoras en pacientes hematológicos de alto riesgo: ¿Qué hemos aprendido en los pasados 10 años?

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 4, pp. 378-386

14. Treatment of buffy coat platelets in platelet additive solution with the mirasol pathogen reduction technology system

    Transfusion Medicine and Hemotherapy, Vol. 40, Núm. 1, pp. 44-48

15. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease

    Blood, Vol. 121, Núm. 12, pp. 2336-2339